Increased plasma 11-deoxycorticosterone during spironolactone medication.

Article Details

Citation

Copy to clipboard

Abshagen U, Sporl S, Schoneshofer M, Oelkers W

Increased plasma 11-deoxycorticosterone during spironolactone medication.

J Clin Endocrinol Metab. 1977 Jun;44(6):1190-3.

PubMed ID

874049 [ View in PubMed

]

Abstract

The increase of plasma deoxycorticosterone (DOC) levels after administration of spironolactone is a real effect and not due to cross-interference of the drug or its metabolites with the DOC-assay. This is proved by in vitro and in vivo results. Of all the metabolites only canrenone interferes to some extent with DOC after liquid-liquid-extraction and paper chromatography. The antiserum, however, is so highly specific, that the final cross-interference of the total procedure amounts to less than 2% of the DOC plasma levels. Moreover, in patients with Addison's disease only a very small increase of DOC plasma levels can be observed after administration of spironolactone in contrast to normal subjects.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Spironolactone	Approved	Deoxycorticosterone	increased	Spironolactone increases the level of Deoxycorticosterone in the blood